215600 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
SillaJen, Inc. develops oncolytic immunotherapeutics virus. Its products include pexa-vec and JX-929. The company was founded on March 28, 2006 and is headquartered in Busan, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
215600 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company